The Global Autoimmune Partnering 2010-2016: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the autoimmune disease partnering deals and agreements entered into by the worlds leading healthcare companies Global Autoimmune Partnering 2010 to 2016 provides the full collection of Autoimmune disease deals signed between the worlds pharmaceutical and biotechnology companies since 2010.
Trends in Autoimmune partnering deals
Financial deal terms for headline, upfront and royalty by stage of development
Autoimmune partnering agreement structure
Autoimmune partnering contract documents
Top Autoimmune deals by value
Most active Autoimmune dealmakers
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensors product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Autoimmune disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Autoimmune deals.
The report includes coverage of the following autoimmune diseases:
Multiple sclerosis, Restless leg syndrome, Eczema, Alopecia, Psoriasis, Celiac disease, Inflammatory bowel disease, Crohns disease, Ulcerative colitis, Glomerulonephritis, Endometriosis, Immune thrombocytopenic purpura, Neutropenia, Graft versus host disease, Scleroderma, Systemic lupus erythematosus, Addisons disease, Diabetes Type 1, Ankylosing spondylitis, Juvenile arthritis, Psoriatic arthritis, Rheumatoid arthritis, Uveitis, Narcolepsy, Idiopathic pulmonary fibrosis, Sarcoidosis, Menieres disease, and other autoimmune disorders.
The report presents financial deal terms values for Autoimmune deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
The initial chapters of this report provide an orientation of Autoimmune dealmaking trends.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in Autoimmune dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.
Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.
Chapter 4 provides a review of the leading Autoimmune deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Autoimmune dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 5 provides comprehensive access to Autoimmune deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of all Autoimmune partnering deals by specific Autoimmune target announced since 2010. The chapter is organized by specific Autoimmune therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided with each report of all Autoimmune partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Autoimmune partnering and dealmaking since 2010.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Autoimmune technologies and products.
Chapter 1 Introduction
Chapter 2 Trends in Oncology dealmaking
2.2. Oncology partnering over the years
2.3. Oncology partnering by deal type
2.4. Oncology partnering by industry sector
2.5. Oncology partnering by stage of development
2.6. Oncology partnering by technology type
2.7. Oncology partnering by therapeutic indication
Chapter 3 Financial deal terms for Oncology partnering
3.2. Disclosed financials terms for Oncology partnering
3.3. Oncology partnering headline values
3.4. Oncology deal upfront payments
3.5. Oncology deal milestone payments
3.6. Oncology royalty rates
Chapter 4 Leading Oncology deals and dealmakers
4.2. Most active in Oncology partnering
4.3. List of most active dealmakers in Oncology
4.4. Top Oncology deals by value
Chapter 5 Oncology contract document directory
5.2. Oncology partnering deals where contract document available
Chapter 6 Oncology dealmaking by therapeutic target
6.2. Deals by Oncology therapeutic target
Appendix 1 Directory of Oncology deals by company A-Z 2010 to 2016
Appendix 2 Directory of Oncology deals by deal type 2010 to 2016
Appendix 3 Directory of Oncology deals by stage of development 2010 to 2016
Appendix 4 Directory of Oncology deals by technology type 2010 to 2016
List Of Figures
Figure 1: Oncology partnering since 2010
Figure 2: Oncology partnering by deal type since 2010
Figure 3: Oncology partnering by industry sector since 2010
Figure 4: Oncology partnering by stage of development since 2010
Figure 5: Oncology partnering by technology type since 2010
Figure 6: Oncology partnering by indication since 2010
Figure 7: Oncology deals with a headline value
Figure 8: Oncology deals with upfront payment values
Figure 9: Oncology deals with milestone payment
Figure 10: Oncology deals with royalty rates
Figure 11: Active Oncology dealmaking activity 2010 to 2016
Figure 12: Top Oncology deals by value since 2010
Notes:Production, means the output of - linolenic acid (GLA)Revenue, means the sales value of - linolenic acid (GLA)This report studies - linolenic acid (GLA) in Global market, especially in North
Notes:Production, means the output of -AmylaseRevenue, means the sales value of -AmylaseThis report studies -Amylase in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with
Notes:Production, means the output of Zirconium Oxide Flap DiscRevenue, means the sales value of Zirconium Oxide Flap DiscThis report studies Zirconium Oxide Flap Disc in Global market, especially in North
2016 Global Oncology Apoptosis Modulators Industry Report is a professional and in-depth research report on the worlds major regional market conditions of the Oncology Apoptosis Modulators industry, focusing on the
Notes:Sales, means the sales volume of Oncology BiosimilarsRevenue, means the sales value of Oncology BiosimilarsThis report studies sales (consumption) of Oncology Biosimilars in Global market, especially in USA, China, Europe,
Notes:Production, means the output of Oncology BiosimilarsRevenue, means the sales value of Oncology BiosimilarsThis report studies Oncology Biosimilars in Global market, especially in North America, Europe, China, Japan, Southeast Asia
If you want to purchase particular section from this report then kindly contact us at email@example.com.